In 2017, the FDA approved Ozempic for patients with type 2 diabetes, with Mounjaros approval following a few years later

Since the calcium in this formula is an all-natural, GRAS certified, plant-derived whole food, it does not have the potential negative effects on arterial calcification that non-food based calcium supplements have.* Additionally, NuMedica has selected a proprietary, clinically effective plant-derived form of D3, instead of the most common source, lanolin (sheeps wool).* D3 is essential for bone health and intestinal calcium absorption.* Osteo Vegan includes an all trans-natural, patented form of K2 as MK7 to support the bodys ability to utilize calcium in the bloodstream.* Patented Albion magnesium is included for its superior absorption compared to other forms such as magnesium carbonate.* This formula contains a broad spectrum of other bone-supporting nutrients and utilizes a proprietary blend of AstraGin and BioPerine the latest in Enhanced Absorption Technologies, for maximum effectiveness.* For best results, use with NuMedicas OsteoV SC, an essential bone support formula.* Click to Read More Power Greens + Reds is an easy mixing, great tasting and energizing phytonutrient powder mix loaded with certified organic, whole food plant extracts.* It also supplies a super blend of completely natural vitamins, ionic trace minerals, enzymes, antioxidants, phytonutrients and symbiotic intestinal flora for energy, metabolism, digestion, detoxification, revitalization and longevity support.* Each scoop of Power Greens + Reds has a high ORAC value, providing powerful antioxidant support

Gastrointestinal side effects occur frequently with tirzepatide
This targeted approach ensures that only the fat cells are affected, leaving other tissues unharmed
The Wegovy pill is here: what the oral semaglutide approval means for weight management services On 11 June 2026, the MHRA approved the first GLP-1 receptor agonist tablet for weight management in the UK, making us the first country in Europe to license it (MHRA, 2026)